Evidence as currency: proving value to regulators and payers

Here is the trap. A 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition →) clearance can say your device works as well as an existing one. A payer hears "as well as" and asks: "So why should I pay *more* than I pay for the existing one?" Clearance answered the regulator's question and created the payer's objection.

What payers actually want: outcomes that cost less

Payers do not buy technology. They buy outcomes that save them money or clearly improve health at an acceptable price. This is often called health economics and outcomes research, or HEOR.

The evidence that convinces a payer usually shows one or more of these:

• Fewer expensive events. Does the device reduce hospital readmissions, complications, or repeat procedures?
• Lower total cost of care. The device might cost more upfront but save money over the full episode of care.
• Real-world durability. Does the benefit hold up outside a pristine trial, in messy everyday practice?

Notice what is missing: "the technology is innovative." Payers do not reward novelty. They reward measurable value.

A concrete illustration

Imagine a continuous glucose monitor for people with diabetes. FDA clearance requires proof that it measures glucose accurately and safely. That is clinical efficacy.

But to get reimbursed broadly, the manufacturer needs different evidence: that patients using the monitor have fewer emergency room visits for dangerous blood sugar swings, better long-term glucose control, and lower total costs over a year. That is reimbursable value. The accuracy data gets you cleared. The outcomes data gets you paid.

The evidence you need is not the evidence you generated

This is the core lesson. The trial that satisfies the FDA is often the *wrong* trial for payers.

Regulatory trials tend to compare a product against a placebo or sham, in carefully selected patients, measuring narrow clinical endpoints. Payers want comparisons against the standard of care (the treatment patients get today), in realistic populations, measuring outcomes that mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.View full definition → to cost.

Smart companies plan *both* evidence packages from the start. Waiting until after clearance to think about payers means running expensive new studies while the cash burns.

The reimbursement machinery

Getting paid in the US involves three practical pieces, often summarized as coding, coverage, and payment:

1. Coding: Is there a billing code that describes your product or procedure? Without a code, providers have no standard way to bill for it.

2. Coverage: Has the payer issued a policy saying they will pay for it, and for which patients?

3. Payment: What is the actual dollar amount, and does it cover the provider's cost?

A gap in any one of these three can stall commercialization even after clearance. The Centers for Medicare & Medicaid Services (CMS) sets influential coverage policy; you can read how Medicare approaches national coverage decisions on the CMS coverage page.

The value dossier: telling the story with evidence

Outside the US, many countries use health technology assessment, or HTA, formal bodies that evaluate whether a new product is worth public money. Examples include NICE in England and IQWiG in Germany. These bodies often demand cost-effectiveness evidence, sometimes expressed as cost per quality-adjusted life year (QALY), a measure combining how long *and* how well a patient lives.

For a global product, this means assembling a value dossier: a structured package of clinical and economic evidence tailored to each market's questions. A device that thrives in the US 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition →) world may hit a wall in an HTA country demanding cost-per-QALY data it never collected.

Provisional coverage and evidence generation

A growing middle path lets promising products enter the market while evidence matures. In the US, CMS has used approaches like Coverage with Evidence Development (CED), where Medicare pays for a product on the condition that the manufacturer keeps gathering outcomes data. This turns coverage into a rolling negotiation: keep proving value, keep getting paid.

For non-technical readers, the takeaway is simple. Evidence is not a one-time hurdle. It is an ongoing currency you must keep earning.

Building an evidence strategy that survives contact with payers

If evidence is currency, you plan your budget before you spend. A few practical principles guide strong biotech and medtech teams.

Start with the payer's spreadsheet, not your lab

Before designing the pivotal trial, ask: *What outcome would make a payer say yes?* Then work backward. If reduced readmissions is the value story, the trial must measure readmissions, not just a lab marker. This is called beginning with the end in mind, and it saves years.

Choose the right comparator

Payers compare you to the current standard of care, so your evidence should too. A trial showing you beat placebo may be regulator-friendly and payer-useless. Whenever feasible, compare against what patients actually receive today.

Collect real-world evidence

Real-world evidence (RWE) comes from data generated in routine care: insurance claims, electronic health records, device registries. Payers increasingly trust RWE because it reflects their actual population, not an idealized trial. Building registries early creates a stream of value evidence over time.

Speak the payer's language

Clinical teams talk in endpoints and p-values. Payers think in budgets, populations, and total cost of care. The value dossier must translate clinical results into economic terms the payer's actuaries recognize. A brilliant result described in the wrong language does not persuade.

Do not confuse enthusiasm with reimbursement

Physicians loving your device is encouraging but not sufficient. Clinicians recommend; payers pay. Many products with devoted early users never reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → scale because the reimbursement pathway was ignored until too late.

Why this matters beyond one product

Investors have learned this lesson the hard way. Increasingly, due diligence for biotech and medtech companies scrutinizes the reimbursement pathway as closely as the clinical data. A strong efficacy story with no plausible payment story is a red flag. Fluency here is now expected of anyone operating in the sector, technical or not.

The discipline is straightforward once you see it: two gatekeepers, two questions, two evidence packages, planned together from day one.

Key Takeaways

• Regulatory clearance and reimbursement are separate hurdles. The FDA asks if a product is safe and effective. Payers ask if it delivers enough value to justify its cost. Passing the first does not guarantee the second.
• Payers reward outcomes that reduce cost or clearly improve health, not novelty. Evidence of fewer complications, lower total cost of care, or durable real-world benefit is the currency that unlocks payment.
• The trial that satisfies regulators is often the wrong trial for payers. Plan both evidence packages from the start, comparing against the real standard of care and measuring outcomes payers care about.
• Coding, coverage, and payment are three distinct steps, and a gap in any one can stall a cleared product. Reimbursement is machinery, not an afterthought.
• Evidence is an ongoing currency, not a one-time hurdle. Real-world evidence, registries, and provisional coverage models mean you keep proving value to keep getting paid.